Regeneron Pharmaceuticals REGN Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.97B-4.0% | $3.12B+25.5% | $2.51B+24.9% | $2.02B+4.5% | $3.09B+18.5% | ||
| $5.79B+10.1% | $5.49B-15.9% | $5.94B-23.7% | $5.47B-30.6% | $5.26B-33.6% | ||
| $8M+186% | —— | $6.7M— | $19.8M+164% | $2.8M— | ||
| $5.73B+3.1% | $5.74B-7.6% | $5.69B-6.9% | $5.61B-1.9% | $5.56B+6.5% | ||
| $3.1B-2.8% | $3.2B+3.7% | $3.25B+7.8% | $3.21B+11.6% | $3.19B+17.6% | ||
| $630.7M-24.8% | $641.5M-27.1% | $710M-17.1% | $752.3M-10.8% | $838.5M+2.9% | ||
| $1.52B+3.7% | $1.64B+22.3% | $1.57B+27.3% | $1.54B+33.7% | $1.47B+32.7% | ||
| $620.9M+32.4% | $474.8M+36.0% | $595.6M+44.6% | $574.3M-15.8% | $468.9M+13.0% | ||
| $18.21B+3.6% | $18.02B-3.4% | $17.98B-7.0% | $16.86B-11.6% | $17.57B-6.9% | ||
| $40.87B+8.9% | $40.56B+7.4% | $40.17B+7.3% | $38.22B+5.9% | $37.55B+9.2% | ||
| $1.03B+45.6% | $939M+18.9% | $903.8M+81.7% | $723.9M+28.9% | $705.5M+5.1% | ||
| $636.2M+2.7% | $553M-11.9% | $545.6M-13.0% | $481.9M-17.8% | $619.3M+19.9% | ||
| —— | $37.8M+24.8% | —— | —— | —— | ||
| $720M— | $0— | —— | —— | —— | ||
| $5.11B+43.2% | $4.37B+10.8% | $4.43B+20.9% | $3.67B+4.5% | $3.57B-0.4% | ||
| $1.99B+0.1% | $1.99B+0.1% | $1.99B+0.1% | $1.99B+0.1% | $1.98B+0.1% | ||
| —— | $720M0.0% | —— | —— | —— | ||
| —— | $266.8M+13.8% | —— | —— | —— | ||
| $0-100% | $720M0.0% | $720M0.0% | $720M0.0% | $720M0.0% | ||
| $2.13B+27.0% | $2.02B+28.5% | $1.86B+20.6% | $1.7B+16.3% | $1.67B+84.3% | ||
| $9.45B+15.8% | $9.3B+10.7% | $9.21B+13.5% | $8.28B+5.1% | $8.16B+10.6% | ||
| $14.4B+9.2% | $14B+8.9% | $13.79B+8.5% | $13.49B+9.5% | $13.19B+10.5% | ||
| $36.42B+12.5% | $35.8B+13.0% | $35.05B+14.0% | $33.68B+14.5% | $32.38B+15.7% | ||
| $11.9M-59.1% | $77.5M+1,081% | $69M+14.6% | $52.5M+175% | $29.1M+138% | ||
| $19.41B+19.7% | $18.61B+22.7% | $17.94B+26.4% | $17.28B+28.5% | $16.22B+26.1% | ||
| $31.42B+6.9% | $31.26B+6.5% | $30.96B+5.6% | $29.94B+6.1% | $29.39B+8.9% | ||
| $40.87B+8.9% | $40.56B+7.4% | $40.17B+7.3% | $38.22B+5.9% | $37.55B+9.2% | ||
| $160.5M+45.9% | $190.2M+36.1% | $169.7M+3.1% | $144.4M-6.5% | $110M-39.1% | ||
| $5.79B+10.1% | $5.49B-15.9% | $5.94B-23.7% | $5.47B-30.6% | $5.26B-33.6% | ||
| $787.9M+1.8% | $727.5M+0.2% | $808.8M+5.5% | $764.4M+6.1% | $773.9M+26.6% | ||
| $571.6M+80.4% | $334M+109% | $316.8M+98.2% | $316.8M+61.0% | $316.8M+330% | ||
| $2.13B+52.9% | $1.82B+60.3% | $1.67B+60.4% | $1.54B+54.6% | $1.39B+196% | ||
| $48.7M— | $34.3M— | —— | —— | —— | ||
| $571.6M+80.4% | $334M+109% | $316.8M+98.2% | $316.8M+61.0% | $316.8M+330% | ||
| $48.7M— | $34.3M— | —— | —— | —— | ||
| $571.6M+80.4% | $334M+109% | $316.8M+98.2% | $316.8M+61.0% | $316.8M+330% | ||
| $4.19B+21.7% | $4.08B+23.0% | $3.85B+27.6% | $3.57B+24.0% | $3.44B+24.5% | ||
| $1.29B+10.3% | $1.26B+9.5% | $1.38B+23.3% | $1.35B+22.6% | $1.17B+10.2% | ||
| $9.79B+5.5% | $10.26B+15.3% | $10.29B+21.1% | $10.06B+30.2% | $9.28B+32.9% | ||
| $2.13B+52.9% | $1.82B+60.3% | $1.67B+60.4% | $1.54B+54.6% | $1.39B+196% | ||
| $5.27B+12.2% | $5.12B+11.3% | $5B+12.7% | $4.84B+12.4% | $4.69B+11.1% | ||
| $2.13B+52.9% | $1.82B+60.3% | $1.67B+60.4% | $1.54B+54.6% | $1.39B+196% | ||
| $225.1M+6.3% | $208.7M+12.4% | $219.2M+5.7% | $206.3M+0.3% | $211.8M+14.0% | ||
| $225.1M+6.3% | $208.7M+12.4% | $219.2M+5.7% | $206.3M+0.3% | $211.8M+14.0% | ||
| $2.72B+21.5% | $2.88B+13.8% | $2.98B+17.3% | $2.46B+4.2% | $2.24B-6.3% | ||
| $225.1M+6.3% | $208.7M+12.4% | $219.2M+5.7% | $206.3M+0.3% | $211.8M+14.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $688.2M-82.2% | —— | $2.16B-25.5% | $2.81B-22.5% | $3.87B+214% | ||
| $15.52B+17.0% | $15.62B+8.9% | $15.43B+3.6% | $13.98B-3.8% | $13.26B-6.7% | ||
| $28.3M+59.9% | $2.5M-93.6% | $6M-76.9% | $10.2M-88.9% | $17.7M-83.1% | ||
| $40.9M-28.2% | $98.5M+227% | $93.2M-7.5% | $77.7M+1,795% | $57M+714% | ||
| $15.52B+17.0% | $15.62B+8.9% | $15.43B+3.6% | $13.98B-3.8% | $13.26B-6.7% | ||
| $9.64B+19.9% | $10.22B+31.0% | $9.52B+32.5% | $8.57B+30.9% | $8.04B+30.0% | ||
| $5.79B+10.1% | $5.49B-15.9% | $5.94B-23.7% | $5.47B-30.6% | $5.26B-33.6% | ||
| $15.53B+16.7% | $15.71B+9.7% | $15.52B+3.7% | $14.05B-2.7% | $13.3B-5.8% | ||
| $98.4M— | $1.5M— | $66M+8,150% | $400K— | —— | ||
| $571.6M+80.4% | $334M+109% | $316.8M+98.2% | $316.8M+61.0% | $316.8M+330% | ||
| $720M— | $0— | —— | —— | —— | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| 30M0.0% | 30M0.0% | 30M0.0% | 30M0.0% | 30M0.0% | ||
| 0— | 0— | 0— | 0— | 0— | ||
| 0— | 0— | 0— | 0— | 0— | ||
| $688.2M-82.2% | —— | $2.16B-25.5% | $2.81B-22.5% | $3.87B+214% | ||
| 34.7M+16.8% | 33.7M+19.5% | 32.7M+21.1% | 31.6M+19.7% | 29.7M+15.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Regeneron Pharmaceuticals's total assets?
- Regeneron Pharmaceuticals (REGN) holds $40.9B in total assets, up 8.8% year over year.
- How much debt does Regeneron Pharmaceuticals have?
- Regeneron Pharmaceuticals carries $2.7B in total debt against $31.4B of shareholders' equity, a debt-to-equity ratio of 0.09.
- How much cash does Regeneron Pharmaceuticals have?
- Regeneron Pharmaceuticals holds $3.0B in cash and equivalents.
- Can Regeneron Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.56 — current assets exceed current liabilities.
- Where does Regeneron Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
